13 April 2022 - Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022. ...
11 March 2022 - There is a wealth of data, reviews, articles, and regulatory guidance on how to conduct clinical trials ...
7 March 2022 - The US FDA is offering funding for several research proposals under the regulatory science pilot for ...
1 March 2022 - First of three Amneal biosimilars expected for U.S. approval and launch in 2022. ...
28 February 2022 - Alvotech is the only known company to have both developed a high-concentration biosimilar to Humira and ...
14 February 2022 - Medscape Education has been awarded a contract from the U.S. FDA for the development of an ...
18 January 2022 - Amid debate over competition in the pharmaceutical industry, a new analysis found just 6% of patents ...
7 January 2022 - The U.S. FDA has issued a complete response letter for the biologics license application for insulin ...
20 December 2021 - Approved for all eligible indications of the reference biological product, Humira (adalimumab). ...
20 December 2021 - Biologics license application is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix. ...
23 November 2021 - In 2019, longtime pharmaceutical industry critic, Peter Bach, took to the Wall Street Journal to declare that ...
16 November 2021 - Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for ...
10 November 2021 - A top official from the US FDA offered a mixed assessment of the agency’s biosimilars program, noting ...
9 November 2021 - Janet Woodcock, MD, acting commissioner of the FDA, delivered an upbeat report on biosimilars and generics progress ...
18 October 2021 - The U.S. FDA approved the first interchangeable biosimilar product to treat certain inflammatory diseases. ...